22 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
in the patient dosed in the 0.6 mg/kg cohort was classified as a Grade 3 event. All infusion reactions and liver transaminase elevations resolved … a partnership or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) of our common stock who is not for U.S
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
in the patient dosed in the 0.6 mg/kg cohort was classified as a Grade 3 event. All infusion reactions and liver transaminase elevations resolved … a partnership or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) of our common stock who is not for U.S
8-K
VERV
Verve Therapeutics Inc
13 Nov 23
Other Events
6:34am
bilirubin levels below the upper limit of normal. The increase in liver transaminases in the patient dosed in the 0.6 mg/kg cohort was classified
424B5
t9qsxyt79p4j
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
ex3mx3gpxzgs2elon6
20 Jul 22
Prospectus supplement for primary offering
4:22pm
10-K
erptvfda8ad njr54
14 Mar 22
Annual report
7:04am
10-Q
jf3dc6w5jtfkoe5cgmn
12 Aug 21
Quarterly report
8:53am
8-K
pwh84iypiml tdrpf2
21 Jun 21
Amendments to Articles of Incorporation or Bylaws
5:06pm
424B4
w0vhw0 4zvqw0k
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
68qnjzw1xl c6q2k4m
14 Jun 21
IPO registration (amended)
6:15am